DEXACURE (Dexamethasone) is a well-tolerated anti-inflammatory corticosteroid which is approximately 25 times as potent as Hydrocortisone and 6-10 times as potent as Prednisolone.
DEXACURE has much less tendency to produce salt and water retention, potassium depletion, edema, anorexia or psychic disturbances.
DEXACURE combines the anti-inflammatory and anti-allergic effect of Dexamethasone with the bacterial effect of Neomycin Sulphate and should be preferred to the plain DEXACURE for topical treatment, whenever the presence of a local infection is suspected.
INDICATIONS AND DOSAGE
Orally and intramuscularly
Palliative treatment of rheumatoid arthritis, rheumatic spondylitis, osteoarthritis, polyarthritis, chronica, psoriatic arthritis, buraitis, tendinitis, synovitis, fibrositis, mucositis, neuritis, bronchial, asthma, rheumatic fever, addison’s disease, still’s disease. Waterhouse-liriderichen’s syndrome, allergies, serum sickness, drug sensitivity.
Depending on the severity of the disease and the susceptibility of the patient, the initial dose usually is 3-4.5mg daily, and up to 6-9mg in severe asthma bronchiale, divided in 4 oral dosed, or given intramuscularly in one dose.
As soon as a good response is noted the daily dosage is reduced gradually by 0.5-1mg every two to three days, until the optimum maintenance dosage is established (usual range between 1 and 4 mg per day).
Intramuscular injection is of value as a substitution for oral therapy in seriously ill or dehydrated patients or in patients undergoing surgery.
Intraarticularly periarticularly intrabuisally or intrasynovially
To relieve inflammation and restore joint, function in rheumatoid arthritis, osteoarthritis, bursitis, synovitis, etc.
Average dosage for intraticular injection ranges from 1-2mg for smaller joints, in acute buraitis a daily injection of 5mg for about 4 days is recommended.
Great technical care should be taken to ensure accurate injection into joint cavitis, bureas or ganglia avoiding blood vessels and other near-by tissues.
Although clinical investigations have shown that DEXACURE produces less undesirable effects than other corticosteroids. It should be borne in mind that DEXACURE in an extremely potent product and that therapeutic doses will, after administration over longer periods effect some depression on the function of the adrenal cortex. The precautions for other corticosteroids should therefore be followed, and it may be necessary to institute rest periods and to stimulate adrenocortical function by use of ACTH.
If signs of infection are present, or if an infection is suspected, DEXACURE should be administered in conjunction with adequate antibacterial therapy. On occassion of therapy the drug should not be stopped abruptly, but should be withdrawn gradually.
Tuberculosis whether active, latent or arrested, other acute or chronic infections, diverticulitis, chickenpox, thrombophialebitis, fresh intestinal anastomoses, peptic ulcer, psychotic tendences, cushing’s syndrome, vaccinia and varicella.
To be used only by or on the prescription of a physician.
To be sold on the prescription of a registered medical practitioner only.
Keep out of the reach of children.
Store in a cool dry place.
Protect from light.
Unicure Pharmaceutical Ltd.
Ikofa Village, Lagos – Benin Expressway, Ijebu-ode, Ogun State, Nigeria.